We commit to disclose conflicts of interest.  We have adopted (and modified slightly to suit a blog) the disclosure policy of the Stanford Law Review, as follows.  We will disclose any financial interest that may be affected by the conclusions reached in our blog entries (or underlying work, if we blog about research we are doing).  We will disclose any source of outside funding for the blog entry (or underlying work) that may have affected or biased the assumptions, results,  or conclusions in the blog entry (or underlying work) — for example, any payment received by an outside organization to complete the work.  We will also disclose any sources of outside funding in the prior 36 months for work that related directly to the topic of a blog entry.  Where confidentiality agreements or privilege considerations preclude us from identifying a particular entity, we will nevertheless disclose the existence of relevant work — and describe the nature of the work to the extent possible, consistent with those obligations.  Finally, our general disclosures are noted below.

Erika Lietzan:  My CV is available here.  Since leaving private practice in 2014, I have served as an expert witness in several cases (disclosed on the CV), and I periodically provide regulatory advice to FDA-regulated companies (directly or through their counsel).

Patti Zettler: My CV is available here.  As noted on my CV and in my bio, I served as an attorney in the FDA’s Office of the Chief Counsel until 2013.  Since then, I served as a consultant to the National Academies of Sciences, Engineering, and Medicine’s Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse in 2016 and 2017, and, after that, have served as an expert witness in several cases (disclosed on my CV).